Business Description
Gossamer Bio Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
4GB.Germany
•
GOSS.USA
Description
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.33 | |||||
| Equity-to-Asset | 0.17 | |||||
| Debt-to-Equity | 4.07 | |||||
| Debt-to-EBITDA | -1.09 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -4.8 | |||||
| 3-Year EPS without NRI Growth Rate | -8.8 | |||||
| 3-Year FCF Growth Rate | -28.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.42 | |||||
| 9-Day RSI | 12.31 | |||||
| 14-Day RSI | 15.3 | |||||
| 6-1 Month Momentum % | 56.32 | |||||
| 12-1 Month Momentum % | 0.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.93 | |||||
| Quick Ratio | 5.93 | |||||
| Cash Ratio | 5.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -318.14 | |||||
| ROA % | -72.08 | |||||
| ROIC % | -729.13 | |||||
| ROC (Joel Greenblatt) % | -1836.8 | |||||
| ROCE % | -77.32 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.93 | |||||
| Price-to-Tangible-Book | 3.93 | |||||
| EV-to-EBIT | -3.74 | |||||
| EV-to-Forward-EBIT | -3.22 | |||||
| EV-to-EBITDA | -3.82 | |||||
| EV-to-Forward-EBITDA | -3.92 | |||||
| EV-to-FCF | -4.45 | |||||
| Price-to-Net-Current-Asset-Value | 4.92 | |||||
| Price-to-Net-Cash | 5.9 | |||||
| Earnings Yield (Greenblatt) % | -26.74 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GOSS
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.89 | ||
| Beta | 0.89 | ||
| Volatility % | 62.65 | ||
| 14-Day RSI | 15.3 | ||
| 14-Day ATR ($) | 1.100262 | ||
| 20-Day SMA ($) | 8.9355 | ||
| 12-1 Month Momentum % | 0.57 | ||
| 52-Week Range ($) | 2.15 - 15.195 | ||
| Shares Outstanding (Mil) | 94.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gossamer Bio Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gossamer Bio Inc Analysis
Share your researchHeadlines
See More
No news.